BAG3 and neoplasm: As shown in Fig. 4A, we observed that intra-tumoral injection of bag3 siRNA-Ad was able to reduce in vivo tumor growth after 44 days of treatment as compared to the scramble-treated (scr siRNA-Ad) and control groups (p<0.001).